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ABSTRACT
Microalbuminuria is the hallmark of the reversible stage of incipient diabetic nephropathy. A cost-
effective and convenient bedside screening test is essential to detect this phase. We used Clinitek
50® which is a semiquantitative strip test to check spot urine sample from 81 patients with albustix
one plus or less. The incidence of Clinitek 50® microalbuminuria was 17%, 18.2% and 75% in 47,
22 and 12 patients with albustix negative, trace or one plus respectively. Nineteen and 13 of the 21
Clinitek 50® positive patients were checked for spot urine DCA 2000® and two 12-hour urine collection
for immunoassay respectively. Around 60% of these samples fell into the microalbuminuria range
and 40% into the overt albuminuria range by either technique. There was no false positive of
Clinitek 50®. The lowest range of microalbuminuria detected by Clinitek 50® was 27 µg/minute (38
mg/day). We concluded that Clinitek 50® is a useful screening test as it is nonexpensive, easily
operated and has a sensitivity close to the lower range of microalbuminuria.
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INTRODUCTION
Microalbuminuria defined as urinary albumin excretion
rate of 30 to 300 mg/day (or 20-200 µg/minute) is one
of the most important single predictor for future
development of overt diabetic nephropathy (1,2,3). The
microalbuminuric phase is a reversible stage in the
development of diabetic nephropathy when appropriate
intervention is being instituted and is regarded as
incipient diabetic nephropathy (4-6). Consequently, early
detection and prompt treatment of incipient diabetic
nephropathy is of ultimate importance in managing
diabetic patients (7-13). However, detection of
microalbuminuria requires the expensive immunoassay
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(IA) measurement of 24-hour urine sample which is
known to be liable to inaccurate collection (14,15).
In the past decade, albumin-creatinine ratio (ACR)
becomes an important tool to quantify microalbuminuria
and to avoid inaccuracies of 24-hour urine collection (16-
19). Clinitek 50® (Bayer, Elkhart, USA) is one of the
current  semiquant i ta t ive  screening  tool  for
microalbuminuria commercially available. This study is
to compare Clinitek 50® with other quantitative methods
in detecting microalbuminuria and to study the
prevalence of incipient diabetic nephropathy in
noninsulin dependent diabetes mellitus (NIDDM)
patients without overt proteinuria.
METHODS
All patients with NIDDM attending the general medical
clinic at Tung Wah Hospital from 30th October 1998 to
27th November 1998 were screened for their previous
albustix results. Patients with previous albustix results
of one plus or less (equivalent to proteinuria ≤ 0.3 g/L)
were recruited in this study. During their routine follow-
up, a spot urine albustix was examined by an experienced
nurse. Urine from patients with the spot urine albustix
result one plus or less would be checked with Clinitek
50®. Urine with ACR between 3.4 mg/mmol to 33.9 mg/
mmol by Clinitek 50® was immediately checked with
DCA 2000® (Bayer, Elkhart, USA). Patients were also
instructed to collect two overnight 12-hour urine samples
for assay of microalbuminuria with IA in Clinical
Biochemistry Laboratory at Queen Mary Hospital.
Clinitek 50® is a semiquantitative test using plastic strips
with two reagent-impregnate pads, one to measure
albumin and another creatinine. An ACR in mg albumin
per mmol creatinine is determined. The color range of
the albumin test is based on the binding of albumin with
a sulfonephthalein dye, resulting in a color shift at a
constant pH. This is referred to as the "Protein Error" of
pH indicators. The creatinine test is based on an enzyme-
linked activity of a copper creatinine complex. The
copper creatinine complex reacts with a hydroperoxide
resulted in a color change ranging from deep gold (30
mg/dL) to deep green (300 mg/dL). Clinitek 50® provides
a categorized result of less than 3.4, 3.4 to 33.9 and more
than 33.9 mg albumin/mmol creatinine. ACR of 3.4 to
33.9 is regarded as the microalbuminuria range.
DCA 2000® is a quantitative test employing an
immunoturbidimetric technique to measure the ACR. A
purified polyclonal goat anti-human albumin anti-serum
antibody binds with albumin in the presence of
polyethylene glycol. The complex formed causes
turbidity which is measured as absorbance. The creatinine
is assayed by colorimetric method based on Benedict/
Behre reaction. Creatinine forms a colored complex with
3,5-dinitrobenzoate at alkaline pH by addition of
potassium hydroxide. Absorbance of this colored
complex is then measured at 531 nm. ACR of 3.4-33.9
mg/mmol is regarded as the microalbuminuria range.
Both Clinitek 50® and DCA 2000® tests was conducted
by the same doctor in the out-patient department without
knowing the identity of the patients.
Two timed overnight 12-hour urine samples were
collected instead of traditional 24-hour urine for IA of
albuminuria. It replaced the standard 24-hour collection
in order to reduce the error from non-compliant
collection. It also fulfills the requirement for the proper
diagnosis of incipient diabetic nephropathy that requires
at least two consecutive urine samples of albumin
excretion rate of 20 to 200 µg/minute as day to day
variation of albumin excretion varies between 30% to
50% (20). Urinary albumin was quantitated with the
Beckman Array 360 Analyzer (Beckman-Coulter Inc.,
USA) employing the rate nephelometry method. The
sensitivity of the method is 2 mg/L.
RESULTS
Urine samples were collected from 81 patients who
fulfilled the inclusion criteria. Of the 81 specimens,
albustix was negative in 47 samples, trace in 22 and one
plus in 12 samples. The incidence of microalbuminuria
by Clinitek 50® method was 17%, 18.2% and 75%
(which also included two cases of Clinitek 50® > 33.9
mg/mmol) in the three groups of patients with negative,
trace and one plus albustix test respectively (Table 1).
None of the urine sample tested negative or trace by
albustix has ACR more than 33.9 mg/mmol by Clinitek
50®.
Of the 21 samples with Clinitek 50® more than 3.4 mg/
mmol, 19 were in the microalbuminuria range
(3.4 mmol/L - 33.9 mmol/L). Eighteen samples were
tested with DCA 2000®. Ten samples (55.6%) fell into
the DCA 2000® microalbuminuria and eight samples
(44.4%) fell into the macroalbuminuria range (> 33.9
mg/mmol). Only 13 patients had sent their two 12-hour
urine collections, of these eight (61.5%) were
microalbuminuric and five (38.5%) had exceeded the
microalbuminuria range, and all of the two consecutive
samples of the same patient showed the same range of
microalbuminuria or macroalbuminuria. None of the
Clinitek 50® positive patients was negative for either
DCA 2000® or IA. The range of microalbuminuria
detected by Clinitek 50® was between 27 µg/minute to
2250 µg/minute (38.8 mg/day-3.24 g/day, mean +SD 603
+871 mg/day and median 253 mg/day) according to IA,
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and the ACR range was between 8.36 mg/mmol to 90.7
mg/mmol according to DCA 2000®. There was no false
positive detected by Clinitek 50® and there was a
significant correlation between the DCA 2000® and IA
results (r = 0.747, p = 0.003) (Fig. 1).
The demographic and clinical data of patients with
positive and negative Clinitek 50® were shown in table
2. With logistic regression, age of patient was the only
signif icant  r isk factor  for  the occurrence of
microalbuminuria or overt proteinuria in these 81 patients
(odds ratio = 1.065, p = 0.031).
DICUSSIONS
Proteinuria can be measured in random samples or 24-
hour collections. Inaccurate urine collection is probably
the most common source of error in quantifying protein
excretion in timed collections (7-13). Total urinary
protein concentration can be estimated with strips at
bedside. There are dipsticks with sensitivity to urinary
protein concentrations as low as 100 mg/L to 200 mg/L
(21). However, at these low levels, the major constituent
of urinary protein is usually Tamm-Horsfall protein and
may not indicate the presence of albumin. On the other
hand, when urine volume is high and the urine is
maximally diluted, a relatively large amount of protein
may be undetected and false negative result will arise.
The consistency of results with the same sample assessed
repeatedly and the precision of reagent strip tests of
urinary total protein concentration are generally poor
(21,22). Inconsistency was dependent on the experience
of the operator. Inconsistency among experienced and
inexperienced technologists can be up to 33% and 93%
respectively (22). ACR has been used to correct problems
arising out of variability in urine volume and
concentration. There is a high degree of correlation
between 24-hour urinary albumin excretion and ACR in
random, single-voided urine samples in patients with
renal disease (23,24). Although ACR may be more
Table 1.  Result of Albustix, Clinitek 50®, DCA 2000® of spot urine
and immunoassay of timed urine collection in 81 NIDDM patients.
Albustix Clinitek 50® DCA 2000® Timed urine collection
n = 81 n = 81 n = 19 n = 13
(0) (0) n = 39 NA NA
n = 47 (+) n = 8 (+) n = 4 (+) n = 4
(++) n = 4 (++) n = 2
Missing n = 2
(Trace) (0) n = 18 NA NA
n = 22 (+) n = 4 (+) n = 3 (+) n = 2
(++) n = 1 (++) n = 1
Missing n = 1
(+) (0) n = 3 NA NA
n = 12 (+) n = 7 (+) n = 3  (+) n = 2
(++) n = 3 (++) n = 2
Missing n = 1  Missing n = 3
(++) n = 2 (+) n = 1
Missing n = 1  Missing n = 2
Abbre: NA = Not applicable
Clinitek 50® and DCA 2000®: (0) = ACR < 3.4 mg/mmol,
  (+) = ACR 3.4-33.9 mg/mmol (++) = ACR > 33.9 mg/mmol
Timed urine collection :
  (+) = Albumin excretion rate 20-200 µg/minute
  (++) = Albumin excretion rate > 200 µg/minute
Figure 1. Correlation of albumin-creatinine ratio from spot urine
by DCA 2000® and albumin excretion rate from two 12-hour urine
collections by immunoassay. The solid line represents the line of
correlation with correlation coefficient, r = 0.747 (p = 0.003). The
area between the two dotted line represents the microalbuminuric
range of albumin excretion rate.
Table 2.  Comparison of demographic and clinical data of 81 NIDDM
patients with normal and abnormal (ACR >3.4 mg/mmol) Clinitek
50® results.
Normal Abnormal P value
No. of patients 60 21
Age 61.3 +11.7 68.6 +9.5 0.012*
Sex, M:F 30:30 13:8 NS
Years with NIDDM 6.7 +6.1 7.0 +4.4 NS
Fasting blood sugar, 8.5 +3.2 7.7 +2.7 NS
   mmol/L
HbA1C, % 8.1 +1.7 7.8 +1.8 NS
Mean BP, mmHg 96.8 +12.5 94.3 +12.4 NS
*by two sample t-test
Ns = Not significant
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quantitative than a simple dipstick test, their use has a
number of limitations. For example, ACR taken in the
morning, first-void urine samples may underestimate 24-
hour protein excretion because the reduction in
proteinuria usually occurs at night (25). The measurement
of creatinine level may introduce another source of error.
The errors of two measurements combined will be greater
than the error of either one alone (25). Despite these
limitations, the ACR may be useful especially in
individuals in whom urine collection is difficult.
Microalbuminuria is the first stage of diabetic
nephropathy that can be detectable clinically. This stage
of incipient diabetic nephropathy is still potentially
salvageable (4-6). More than 30% of insulin dependent
diabetes mellitus (IDDM) patients (7,26-28) and 25%
of NIDDM patients will develop overt diabetic
nephropathy ultimately (8,29-31). The routine use of
albustix at clinic visits is convenient and inexpensive
but is unfortunately insensitive for detecting
microalbuminuria. The traditional 24-hour urine
collection for microalbumin assay is too time consuming,
subject to timing and collection inaccuracies (7-13), and
is also too expensive for screening large number of
patients with negative albustix. Therefore it is not a
suitable screening test. A cost-effective test which allows
large scale screening in an out-patient basis is of vital
importance to detect this potentially salvageable phase
of incipient diabetic nephropathy.
In our small scale survey, we find that there is a good
concordance between the Clinitek 50® results with either
DCA 2000® or IA from two 12-hour urine collections.
Although the specificity and sensitivity of this test cannot
be generated from our data, the range it covered was as
low as 38 mg/day. Therefore we believe that Clinitek
50® is useful for detection of microalbuminuria. The test
is easy and can be performed at bedside. It takes 20
seconds per test and costs only HK$15 per strip. The
DCA 2000® is much more time-consuming. It takes
around 10 minutes for one assay and costs HK$73 per
test.
The prevalence of microalbuminuria as detected by
Clinitek 50® in this study was around 18% for both
groups of patients with negative or trace albustix test.
The distinction between negative and trace albustix test
is largely subjective and difficult. They may probably
be better considered under the same category. Around
40% of these Clinitek 50® microalbuminuric patients
actually had proteinuria exceeding the microalbuminuria
range by DCR 2000® or by IA. This may mean that
around 11% and 7% of patients with negative or trace
albustix results have already developed incipient and
overt diabetic nephropathy respectively. This prevalence
of microalbuminuria in patients without overt proteinuria
is quite similar to those reported by Tiu et al in Hong
Kong (14.6%-16%) (32) and by Leong et al in Singapore
(18%) (33). Although Clinitek 50® does not distinguish
microalbuminuria from overt proteinuria very well, it is
still useful in detecting low grade microalbuminuria as
it was positive in a patient with albumin excretion rate
as low as 27 µg/minute (38 mg/day) in this study. We
concluded that Clinitek 50® is a convenient and cost-
effective tool for screening of microalbuminuria in
patients with negative or trace albustix results at regular
intervals. If it is Clintek 50® positive, the result should
further be confirmed by two 24-hour or 12-hour overnight
urine collections for microalbuminuria assay or other
more specific quantitative assays of spot urine sample
like DCA 2000®.
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